We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor ...

Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aura Biosciences Inc (AURA – Research Report) ...

Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...

SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued on Monday,RTT News reports.